Valuation: Sanofi

Capitalization 87.74B 103B 80.29B 75.79B 141B 9,753B 143B 952B 371B 4,685B 387B 379B 16,174B P/E ratio 2026 *
10.7x
P/E ratio 2027 * 9.92x
Enterprise value 100B 118B 91.51B 86.38B 161B 11,116B 163B 1,086B 423B 5,339B 442B 432B 18,434B EV / Sales 2026 *
2.14x
EV / Sales 2027 * 1.98x
Free-Float
88.2%
Yield 2026 *
5.87%
Yield 2027 * 6.19%
1 day-0.87%
1 week-8.42%
Current month-8.42%
1 month-9.66%
3 months-8.96%
6 months-14.44%
Current year-11.63%
1 week 72.74
Extreme 72.74
80.56
1 month 72.74
Extreme 72.74
84.04
Current year 72.74
Extreme 72.74
84.97
1 year 72.74
Extreme 72.74
94.1
3 years 72.74
Extreme 72.74
110.88
5 years 72.74
Extreme 72.74
110.88
10 years 62.5
Extreme 62.5
110.88
Manager TitleAgeSince
Chief Executive Officer 64 01/05/2026
Director of Finance/CFO 64 01/04/2024
Chief Tech/Sci/R&D Officer 51 11/09/2023
Director TitleAgeSince
Director/Board Member 60 30/04/2019
Director/Board Member 56 28/04/2020
Director/Board Member 64 28/04/2020
Change 5d. change 1-year change 3-years change Capi.($)
-0.87%-8.42%-21.33%-27.51% 103B
-2.72%-1.54%+29.12%+121.40% 846B
-0.53%-2.58%+43.51%+37.42% 533B
-0.57%-2.44%+9.18%+37.27% 356B
-0.94%-0.97%+22.40%+11.18% 324B
+0.23%-1.24%+30.31%+12.00% 282B
+0.05%-2.19%+24.69%+21.29% 278B
-0.82%-0.70%+46.61%-5.15% 275B
-1.76%+4.42%-34.66%-49.15% 203B
+0.79%+0.57%+24.76%+41.49% 179B
Average -0.71%-1.51%+17.46%+20.02% 337.86B
Weighted average by Cap. -1.05%-1.48%+24.20%+42.04%

Financials

2026 *2027 *
Net sales 46.72B 54.99B 42.75B 40.35B 75.27B 5,193B 75.94B 507B 198B 2,494B 206B 202B 8,612B 49.58B 58.35B 45.37B 42.82B 79.88B 5,511B 80.58B 538B 210B 2,647B 219B 214B 9,139B
Net income 8.15B 9.59B 7.46B 7.04B 13.13B 906B 13.24B 88.44B 34.48B 435B 35.97B 35.22B 1,502B 8.81B 10.38B 8.07B 7.61B 14.2B 980B 14.33B 95.69B 37.3B 471B 38.93B 38.11B 1,625B
Net Debt 12.26B 14.43B 11.22B 10.59B 19.76B 1,363B 19.93B 133B 51.89B 655B 54.14B 53.01B 2,260B 10.4B 12.24B 9.52B 8.98B 16.75B 1,156B 16.9B 113B 44B 555B 45.91B 44.95B 1,917B
Logo Sanofi
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (81.8%): prescription drugs for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases; - human vaccines (18.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas. At the end of 2025, the group had 37 production sites worldwide. Net sales are distributed geographically as follows: France (3.9%), Europe (17.1%), the United States (50.8%), China (6%) and other (22.2%).
Employees
74,846
Date Price Change Volume
08/05/26 73.10 -0.87% 2,342,546
07/05/26 73.74 -1.21% 3,239,592
06/05/26 74.64 +0.65% 2,422,805
05/05/26 74.16 -4.69% 3,529,693
04/05/26 77.81 -2.52% 2,394,333
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
73.10EUR
Average target price
97.10EUR
Spread / Average Target
+32.83%

Quarterly revenue - Rate of surprise